Short answer
Nutex Health Inc. (NUTX) filed its Q3 2025 10-Q quarterly report on Nov 19, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $268M (up 239.9% year over year) with net income of $55M.
Q3 2025 key financials · XBRL
- Revenue
- $268M
- +239.9% YoY · +9.8% QoQ
- Net income
- $55M
- +730.8% YoY · +598.8% QoQ
- Operating margin
- 48.7%
- Gross margin
- 57.8%
- EPS (diluted)
- $8.32
- +572.7% YoY · +513.9% QoQ
Source: XBRL data from the Nutex Health Inc. (NUTX) Q3 2025 10-Q on SEC EDGAR. USD.
Nutex Health Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $267.8M vs $78.8M YoY; hospital division $260.2M vs $71.7M
- Hospital division best performer, segment gross profit $154.1M vs $21.4M
- Net income attributable to Nutex $55.4M vs $(8.8)M; diluted EPS $8.27 vs $(1.72)
- Q3 arbitration costs $41.9M; stock repurchase authorization up to $25.0M
- Outlook: three new hospitals expected by end-2025; regulatory changes may pressure revenue and margins
Risk Factors
- New short-seller risk triggered by July 22, 2025 report; stock fell 16.4% to $92.90
- New litigation risk triggered by August 22, 2025 securities class action and September 2025 derivative suits
- Dilution risk: seven hospitals could require 1,359,624 earn-out shares, representing 19.7% of outstanding shares
- Additional dilution risk: three hospitals may require approximately 218,600 shares by December 31, 2026
- Regulatory exposure: short-seller allegations could prompt SEC investigations and substantial defense costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nutex Health Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.